If approved, Celltrion's CT-P16 would be the fourth bevacizumab biosimilar to reach the market.
New phase 3 data show Celltrion’s proposed biosimilar of bevacizumab produced an objective response rate (ORR) equivalent to the reference product Avastin in patients with metastatic or recurrent non-small cell lung cancer (NSCLC). The study was presented Friday during the American Association of Cancer Research (AACR) annual meeting in New Orleans, Louisiana.
Based on these results, Celltrion has completed applications for the product, known as CT-P16, in the United States, the European Union, and Korea, for all of Avastin’s indications, according to a statement released to media in Asia after The Center for Biosimilars® asked for comment on the results.
“As CT-P16 proved similar in safety to the original drug in phase 3 large-scale global clinical trials, we plan to speed up the approval process through consultation with regulatory authorities in each country," the statement said. “We will do our best to ensure the prompt supply of high-quality anticancer antibody biosimilars when we obtain approval from each country.”
Celltrion officials announced the phase 3 study back in 2019, following positive phase 1 results for their bevacizumab biosimilar. At that time, competitors for Avastin had not reached the market. Since then, Amgen’s Mvasi and Pfizer’s Zirabev have been approved for indications that include metastatic or recurrent NSCLC. Another biosimilar from Boehringer-Ingelheim is no longer under development. Celltrion, however, has said previously that the company plans to compete with other biosimilars on price.
The double-blind, randomized, multicenter study compared CT-P16, the investigational biosimilar, with the FDA-approved version of bevacizumab; both were used in combination with carboplatin and paclitaxel up to 6 cycles (induction period), followed by maintenance CT-P16 or bevacizumab monotherapy until patients experienced disease progression or unacceptable toxicity.
The study’s primary end point was ORR during the induction period; this was defined as complete or partial responses using RECIST v1.1 as assessed by an independent reviewer. Secondary end points were quality of life (QOL), pharmacokinetics (PK), safety, and immunogenicity.
Investigators randomized a total of 689 patients, with 342 receiving the biosimilar and 347 receiving bevacizumab. According to the AACR abstract, baseline characteristics were well balanced. Results were similar between the 2 treatment arms:
“This study demonstrated that CT-P16 is equivalent to [Avastin] as measured by ORR in patients with metastatic or recurrent adenocarcinoma of the lung,” the authors wrote.
Avastin, made by Roche, brought in $7 billion for the company in 2018, according to Forbes.
Reference
Ohe Y, Bondarenko I, Andric Z, et al. Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin), in patients with metastatic or recurrent non-small cell lung cancer (NSCLC). Presented at: the American Association of Cancer Research Annual Meeting; April 8-13, 2022; New Orleans, LA; Abstract CT551. https://www.abstractsonline.com/pp8/#!/10517/presentation/20290
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.